Maravai Lifesciences price target lowered to $4 from $5 at Stifel

Stifel lowered the firm’s price target on Maravai Lifesciences (MRVI) to $4 from $5 and keeps a Buy rating on the shares. Maravai posted a Q3 miss with revenue of $42M coming in below the $50M consensus view, the analyst tells investors in a research note. The firm added that Maravai looks “fairly washed out” at the $2-$3 level, but with a new management team and low visibility, the shares are appropriate for only the intrepid right now.